



Third Quarter Results Fiscal Year 2016

August 4, 2016

Forward-Looking Statements

- These materials include forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our third quarter earnings release and in our recent SEC filings.

Non-GAAP Financial Measures

- These materials also include Non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found herein, or in our earnings release and the financial schedules attached thereto.
- A reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures are omitted from the financial schedules attached hereto as we are unable to provide such reconciliations without unreasonable efforts. Sufficient information is not available to calculate certain forward-looking adjustments required for such reconciliations, including future restructuring charges and acquisition-related costs. We expect these forward-looking adjustments could have a potentially significant impact on our future GAAP financial results.
- A copy of the press release, including the financial schedules, is posted on the "Investors" section of the BD.com website.

Non-GAAP Financial Measures

- Certain financial information excludes the impact of the following items:
 1. Foreign currency translation.
 2. All adjustments to current and prior year as noted on the "Adjustment Reconciliation" schedules in the appendix of this presentation, including deferred revenue adjustments associated with the write-down of CareFusion's deferred revenue balance to reflect a fair value measurement as of the acquisition date. The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts. Revenue for these contracts is typically deferred and recognized over the term of the contracts.



FXN = Estimated foreign exchange-neutral currency growth. \$ = Dollars in millions except per share data.

Comparable FXN = Estimated foreign exchange-neutral currency growth including BD and CareFusion in the current and prior year periods.

Note: All figures on accompanying slides are rounded. Totals may not add due to rounding. Percentages are based on un-rounded figures.

Executive Overview

Vincent A. Forlenza

Chairman, CEO and President



Q3 FY 2016 Business Highlights

- ◆ Solid Q3 results
- ◆ Performance from both segments driving solid organic revenue growth and strong EPS
- ◆ Significant operating efficiencies driving third quarter operating margin expansion
- ◆ Increasing key strategic investments in R&D
- ◆ Confidence in FY 2016 guidance

Q3 FY 2016 Financial Highlights

As Adjusted	Third Quarter				Year-to-Date			
	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
Revenues	\$3,200	2.2%	3.1%	4.0% ⁽¹⁾	\$9,263	28.0%	32.2%	3.7%
EPS	\$2.35	14.6%	19.5%	N/A	\$6.48	24.1%	33.9%	N/A

- ◆ Strong Q3 EPS of \$2.35 and 19.5% FXN growth



(1) BDX Comparable FXN Growth is 3.9%, which includes the impact of the divestiture of the Spine business. On an organic basis, which excludes the revenues of the Spine business in the current and prior year periods, comparable FXN revenue growth is 4.0%.

Financial Update

Christopher Reidy

Chief Financial Officer and
Executive Vice President of Administration



FY 2016 Adjusted Revenues by Segment

	Third Quarter				Year-to-Date			
As Adjusted	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
Total Revenues	\$3,200	2.2%	3.1%	4.0%⁽¹⁾	\$9,263	28.0%	32.2%	3.7%
Medical	2,237	1.1%	1.9%	3.0%	6,431	46.5%	50.8%	3.7%
Life Sciences	963	4.6%	6.0%	6.0%	2,832	(0.5%)	3.7%	3.7%



(1) BDX Comparable FXN Growth is 3.9%, which includes the impact of the divestiture of the Spine business. On an organic basis, which excludes the revenues of the Spine business in the current and prior year periods, comparable FXN revenue growth is 4.0%.

FY 2016 Adjusted U.S. and International Revenues

	Third Quarter				Year-to-Date			
As Adjusted	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
U.S.	\$1,737	1.8%	1.8%	3.4%	\$5,156	49.5%	49.5%	3.5%
Medical	1,309	1.4%	1.4%	3.4%	3,862	75.9%	75.9%	3.6%
Life Sciences	428	3.4%	3.4%	3.4%	1,294	3.2%	3.2%	3.2%
International	\$1,463	2.5%	4.6%	4.6%	\$4,107	8.5%	16.5%	3.8%
Medical	928	0.8%	2.6%	2.6%	2,569	17.1%	25.6%	3.8%
Life Sciences	535	5.7%	8.1%	8.1%	1,538	(3.4%)	4.0%	4.0%

FY 2016 Developed & Emerging Markets

	Third Quarter			Year-to Date		
As Adjusted	\$	% of BD Revenues	Comparable FXN Growth %	\$	% of BD Revenues	Comparable FXN Growth %
Developed Markets	\$2,715	85%	3.7%	\$7,870	85%	3.5%
Emerging Markets	\$485	15%	5.2%	\$1,393	15%	4.2%
China	\$170	5%	9.5%	\$496	5%	7.8%



Note: Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and certain countries within Asia Pacific, excluding Australia, New Zealand, Korea, Singapore, Hong Kong, Taiwan & Japan.

FY 2016 Safety Revenues

	Third Quarter			Year-to-Date			
	\$	Growth %	FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
Total Safety	\$784	7.6%	8.9%	\$2,254	21.7%	25.9%	6.8%
By Geography							
U.S.	450	5.3%	5.3%	1,340	30.1%	30.1%	4.6%
International	334	10.8%	13.9%	914	11.1%	20.7%	10.1%
By Segment							
Medical	493	8.6%	9.6%	1,425	38.2%	42.2%	7.7%
Life Sciences	291	5.9%	7.6%	829	0.9%	5.4%	5.4%

- Emerging Markets Safety grew 19.6% in Q3 and 15.4% Year-to-Date



Q3 FY 2016 Adjusted Income Statement



	Favorable (Unfavorable)				
	Adjusted Q3 FY 2016	Adjusted Q3 FY 2015	\$ Change	% Change	FXN % Change
Revenues Organic Growth	\$3,200	\$3,133	\$67	2.2%	3.1% 4.0% ⁽¹⁾
Gross Profit	1,684	1,615	69	4.3%	6.3%
% of Revenues	52.6%	51.5%			
SSG&A	728	748	21	2.7%	1.9%
% of Revenues	22.7%	23.9%			
R&D	207	179	(27)	(15.3%)	(15.3%)
% of Revenues	6.5%	5.7%			
Operating Income	749	687	62	9.0%	12.8%
% of Revenues	23.4%	21.9%			
Tax Rate	21.3%	24.8%			
Adjusted EPS	\$2.35	\$2.05	\$0.30	14.6%	19.5%

(1) BDX Comparable FXN Growth is 3.9%, which includes the impact of the divestiture of the Spine business. On an organic basis, which excludes the revenues of the Spine business in the current and prior year periods, comparable FXN revenue growth is 4.0%.



Note: Adjusted Q3 FY 2015 results reflect the impact of a reclass from SSG&A and R&D to COGS associated with the alignment of accounting policies in connection with acquisition integration.

Q3 FY 2016 Adjusted Margin Changes Year-Over-Year



- ◆ ~280 bps underlying operating margin expansion through Q3 YTD



Guidance

Christopher Reidy


Chief Financial Officer

Executive Vice President of Administration



FY 2016 Adjusted Revenue Guidance


FY15-16 Adjusted Quarterly Revenues



Sequentially increasing revenues each quarter throughout FY16



FY 2016 Adjusted EPS Guidance



- Raise currency-neutral EPS guidance to \$9.08 to \$9.15
- Maintain adjusted EPS guidance of \$8.50 to \$8.57



FY 2016 Guidance

As Adjusted	May Guidance	August Update
Total Revenues – FXN	24.5% to 25.0%	24.5% to 25.0%
Total Revenues – Rptd	21.5% to 22.0%	21.0% to 21.5%
Medical Revenues – FXN	36.0% to 36.5%	36.0% to 36.5%
Comparable Organic Total Revenues – FXN⁽¹⁾	4.5% to 5.0%	4.5% to 5.0%
Comparable Medical Revenues – FXN ⁽²⁾	4.5% to 5.0%	4.5% to 5.0%
Life Sciences Revenues – FXN	4.0% to 4.5%	3.5% to 4.0%
Gross Profit	52.0% to 52.5%	52.0% to 52.5%
SSG&A	24.0% to 24.5%	24.0% to 24.5%
R&D	6.0% to 6.5%	~6.5%
Operating Income Underlying Margin Expansion ⁽³⁾	21.0% to 22.0% +170 to 190 bps	21.0% to 22.0% +200 to 210 bps
Effective Tax Rate	21.0% to 22.0%	21.0% to 22.0%
EPS	\$8.50 to \$8.57	\$8.50 to \$8.57
EPS – FXN	\$9.01 to \$9.08	\$9.08 to \$9.15
EPS – FXN Accretion	~22% Accretion	~22% Accretion
EPS – FXN Growth	~26% to 27%	~27% to 28%
Operating Cash Flow	~\$2.6B	~\$2.6B
Capital Expenditures	~\$650-700M	~\$650-700M
Interest/Other, net	~(\$400M)	~(\$400M)
Share Count	~217M	~217M

Note: Guidance updates denoted in bold.



(1) Excludes the impact from a distribution agreement change in the Respiratory Solutions business, closed divestitures, and non-annualized acquisitions.

(2) Excludes the impact from a distribution agreement change in the Respiratory Solutions business.

(3) Underlying Margin Expansion excludes currency and pension impacts.

Executive Overview

Vincent A. Forlenza

Chairman, CEO and President



Q3 FY2016 Business Update: Growth and Strategic Initiatives

New Product Innovation



- 100+ hospitals implemented interoperability for Alaris™ System infusion pump platform
- Introduction of BD FACSMelody™ cell sorter
- Submitting HPV assay for BD Max™ to FDA

Strategic / Business Initiatives



- Creation of Respiratory Solutions JV on-track
- Over 50 CFN product registered and on-track to register additional 25 CFN products

Partnerships / Collaborations



- On-track for launch of insulin infusion sets
- Agreement with Check-Points B.V. on the development of Carba-R test for BD Max™




Q3 FY2016 Business Update: Operational Efficiencies

Operational Efficiencies



- G&A functional transformation continues:
 - Expanding and leveraging Global Shared Services (GSS) and Centers of Excellence (CoE)
 - Focus on lean and efficient end-to-end processes
- Continued manufacturing footprint optimization with planned closure of two plants
- Remain on-track to achieve FY16 cost synergies

Operating Margin Expansion (FXN)



Key Takeaways

- ◆ Solid Q3 results
- ◆ Good performance from both segments highlights our diverse geographic and product portfolio
- ◆ Significant operating efficiencies driving third quarter operating margin expansion
- ◆ Increasing key strategic investments in R&D
- ◆ Confidence in FY 2016 guidance

Advancing
the World
of Health



Q3 FY 2016 & FY 2015 Adjustment Reconciliations

(Unaudited; Amounts in millions, except per share data)

		Three Months Ended June 30, 2016										
		Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Expense, Net	Income Tax Provision	Net Income	Diluted Earnings per Share
Reported \$ for Three Months Ended June 30, 2016		\$ 3,198	\$ 1,547	\$ 728	\$ 207	\$ 96	\$ 516	\$ (97)	\$ (1)	\$ 32	\$ 390	\$ 1.80
<i>Reported % of Revenues</i>			48.4%	22.8%	6.5%		16.1%				12.2%	
<i>Reported effective tax rate</i>										7.6%		
Specified items:												
Purchase accounting adjustments pre-tax ⁽¹⁾		2	136	1	-	-	135	(8)	-	-	127	0.58
Restructuring costs pre-tax ⁽²⁾		-	-	-	-	(49)	49	-	-	-	49	0.23
Integration costs pre-tax ⁽²⁾		-	-	-	-	(40)	40	-	-	-	40	0.18
Transaction costs pre-tax ⁽²⁾		-	-	-	-	(7)	7	-	-	-	7	0.03
Pension settlement charges pre-tax ⁽³⁾		-	1	(1)	-	-	3	-	-	-	3	0.01
Income tax benefit of special items		-	-	-	-	-	-	-	-	106	(106)	(0.49)
Adjusted \$ for Three Months Ended June 30, 2016		\$ 3,200	\$ 1,684	\$ 728	\$ 207	\$ -	\$ 749	\$ (105)	\$ (1)	\$ 138	\$ 510	\$ 2.35
<i>Adjusted % of Adjusted Revenues</i>			52.6%	22.7%	6.5%		23.4%			21.3%	15.9%	
<i>Adjusted effective tax rate</i>												
		Three Months Ended June 30, 2015										
		Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax (Benefit) Provision	Net Income	Diluted Earnings per Share
Reported \$ for Three Months Ended June 30, 2015		\$ 3,120	\$ 1,174	\$ 751	\$ 178	\$ 108	\$ 137	\$ (105)	\$ 5	\$ (23)	\$ 62	\$ 0.29
<i>Reported % of Revenues</i>			37.6%	24.1%	5.7%		4.4%				2.0%	
<i>Reported effective tax rate</i>										-60.0%		
Specified items:												
Purchase accounting adjustments pre-tax ⁽⁴⁾		13	444	(3)	-	-	447	(8)	-	-	439	2.04
Restructuring costs pre-tax ⁽²⁾		-	-	-	-	(75)	75	-	-	-	75	0.35
Integration costs pre-tax ⁽²⁾		-	-	-	-	(24)	24	-	-	-	24	0.11
Transaction costs pre-tax ⁽²⁾		-	-	-	-	(9)	9	-	-	-	9	0.04
Financing costs pre-tax ⁽²⁾		-	-	-	-	-	-	5	-	-	5	0.02
Employee termination cost-related amounts pre-tax ⁽⁵⁾		-	(3)	-	2	-	(5)	-	-	-	(5)	(0.02)
Income tax benefit of special items		-	-	-	-	-	-	-	-	169	(169)	(0.79)
Adjusted \$ for Three Months Ended June 30, 2015		\$ 3,133	\$ 1,615	\$ 748	\$ 179	\$ -	\$ 687	\$ (108)	\$ 5	\$ 145	\$ 441	\$ 2.05
<i>Adjusted % of Revenues</i>			51.5%	23.9%	5.7%		21.9%			24.8%	14.1%	
<i>Adjusted effective tax rate</i>												
		Three Months Ended June 30, 2016 versus June 30, 2015										
Adjusted \$ change		C=A-B \$ 67	\$ 69	\$ 21	\$ (27)	\$ -	\$ 62	\$ 3	\$ (6)	\$ 7	\$ 69	\$ 0.30
Adjusted % change		D=C/B 2.2%	4.3%	2.7%	(15.3%)	-	9.0%	2.7%	NM	5.1%	15.7%	14.6%
Foreign currency translation impact		E \$ (29)	\$ (32)	\$ 6	\$ -	\$ -	\$ (26)	\$ -	\$ (2)	\$ 6	\$ (22)	\$ (0.10)
Adjusted foreign currency neutral \$ change		F=C-E \$ 96	\$ 101	\$ 14	\$ (27)	\$ -	\$ 88	\$ 3	\$ (4)	\$ 1	\$ 91	\$ 0.40
Adjusted foreign currency neutral % change		G=F/B 3.1%	6.3%	1.9%	(15.3%)	-	12.8%	2.7%	(78.9%)	0.9%	20.6%	19.5%

⁽¹⁾ Includes non-cash amortization expense of \$131 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of (\$0) million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$4 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

⁽²⁾ Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

⁽³⁾ Represents pension settlement charges associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost.

⁽⁴⁾ Represents non-cash amortization expense of \$148 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$291 million pre-tax to reflect CareFusion's inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date.

⁽⁵⁾ Represents an adjustment to the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014.

NM - Not Meaningful



Q3 YTD FY 2016 & FY 2015 Adjustment Reconciliations

(Unaudited; Amounts in millions, except per share data)

Nine Months Ended June 30, 2016												
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share	
Reported \$ for Nine Months Ended June 30, 2016	\$ 9,252	\$ 4,438	\$ 2,209	\$ 575	\$ 321	\$ 1,334	\$ (293)	\$ 10	\$ 107	\$ 958	\$ 4.41	
<i>Reported % of Revenues</i>		48.0%	23.9%	6.2%		14.4%				10.4%		
<i>Reported effective tax rate</i>									10.1%			
Specified items:												
Purchase accounting adjustments pre-tax ⁽¹⁾	12	435	17	-	-	419	(24)	-	-	395	1.82	
Restructuring costs pre-tax ⁽²⁾	-	-	-	-	(198)	198	-	-	-	198	0.91	
Integration costs pre-tax ⁽²⁾	-	-	-	-	(115)	115	-	-	-	115	0.53	
Transaction costs pre-tax ⁽²⁾	-	-	-	-	(7)	7	-	-	-	7	0.03	
Pension settlement charges pre-tax ⁽³⁾	-	1	(1)	-	-	3	-	-	-	3	0.01	
Income tax benefit of special items	-	-	-	-	-	-	-	-	270	(270)	(1.24)	
Adjusted \$ for Nine Months Ended June 30, 2016	\$ 9,263	\$ 4,875	\$ 2,224	\$ 575	\$ -	\$ 2,076	\$ (317)	\$ 10	\$ 377	\$ 1,406	\$ 6.48	
<i>Adjusted % of Adjusted Revenues</i>		52.6%	24.0%	6.2%		22.4%				15.2%		
<i>Adjusted effective tax rate</i>									21.1%			
Nine Months Ended June 30, 2015												
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share	
Reported \$ for Nine Months Ended June 30, 2015	\$ 7,222	\$ 3,265	\$ 1,806	\$ 436	\$ 244	\$ 779	\$ (272)	\$ 23	\$ 35	\$ 514	\$ 2.52	
<i>Reported % of Revenues</i>		45.2%	25.0%	6.0%		10.8%				7.1%		
<i>Reported effective tax rate</i>									6.4%			
Specified items:												
Purchase accounting adjustments pre-tax ⁽⁴⁾	13	480	(3)	-	-	483	(8)	(9)	-	466	2.28	
Restructuring costs pre-tax ⁽²⁾	-	-	-	-	(136)	136	-	-	-	136	0.67	
Integration costs pre-tax ⁽²⁾	-	-	-	-	(55)	55	-	-	-	55	0.27	
Transaction costs pre-tax ⁽²⁾	-	-	-	-	(52)	52	-	-	-	52	0.26	
Financing costs pre-tax ⁽²⁾	-	-	-	-	-	-	107	-	-	107	0.53	
Employee termination cost-related amounts pre-tax ⁽⁵⁾	-	(3)	-	2	-	(5)	-	-	-	(5)	(0.02)	
Litigation-related Charge pre-tax ⁽⁶⁾	-	-	(12)	-	-	12	-	-	-	12	0.06	
Income tax benefit of special items	-	-	-	-	-	-	-	-	277	(277)	(1.36)	
Dilutive Share Impact ⁽⁷⁾	-	-	-	-	-	-	-	-	-	-	0.02	
Adjusted \$ for Nine Months Ended June 30, 2015	\$ 7,235	\$ 3,741	\$ 1,791	\$ 437	\$ -	\$ 1,512	\$ (173)	\$ 14	\$ 312	\$ 1,062	\$ 5.22	
<i>Adjusted % of Revenues</i>		51.7%	24.8%	6.0%		20.9%				14.7%		
<i>Adjusted effective tax rate</i>									22.7%			
Nine Months Ended June 30, 2016 versus June 30, 2015												
Adjusted \$ change	C=A-B	\$ 2,029	\$ 1,134	\$ (432)	\$ (138)	\$ -	\$ 563	\$ (144)	\$ (3)	\$ (65)	\$ 345	\$ 1.26
Adjusted % change	D=C/B	28.0%	30.3%	(24.1%)	(31.5%)	-	37.3%	(83.3%)	(24.1%)	(20.7%)	32.5%	24.1%
Foreign currency translation impact	E	\$ (304)	\$ (208)	\$ 70	\$ 5	\$ -	\$ (133)	\$ -	\$ (10)	\$ 32	\$ (112)	\$ (0.51)
Adjusted foreign currency neutral \$ change	F=C-E	\$ 2,333	\$ 1,342	\$ (502)	\$ (143)	\$ -	\$ 696	\$ (144)	\$ 7	\$ (96)	\$ 456	\$ 1.77
Adjusted foreign currency neutral % change	G=F/B	32.2%	35.9%	(28.0%)	(32.7%)	-	46.0%	(83.5%)	47.3%	(30.9%)	43.0%	33.9%

⁽¹⁾ Includes non-cash amortization expense of \$416 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$5 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$26 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

⁽²⁾ Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

⁽³⁾ Represents pension settlement charges associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost.

⁽⁴⁾ Includes non-cash amortization expense of \$184 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$291 million pre-tax to reflect CareFusion's inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes an acquisition-date accounting gain of \$9 million pre-tax related to a previously held equity investment.

⁽⁵⁾ Represents an adjustment to the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014.

⁽⁶⁾ Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

⁽⁷⁾ Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-date adjusted diluted average shares outstanding (in thousands) is 197,390.



Q3 FY 2016 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

(Unaudited)

	Three Months Ended June 30,						
	2016	2015	Growth	Foreign Currency Translation	Foreign Currency Neutral Growth	Growth %	Foreign Currency Neutral Growth %
Reported Diluted Earnings per Share	\$ 1.80	\$ 0.29	\$ 1.51	\$ (0.10)	\$ 1.61	NM	NM
Purchase Accounting Adjustments (\$127 million and \$439 million pre-tax, respectively)	0.58 ⁽¹⁾	2.04 ⁽²⁾					
Restructuring Costs (\$49 million and \$75 million pre-tax, respectively) ⁽³⁾	0.23	0.35					
Integration Costs (\$40 million and \$24 million pre-tax, respectively) ⁽³⁾	0.18	0.11					
Transaction Costs (\$7 million and \$9 million pre-tax, respectively) ⁽³⁾	0.03	0.04					
Pension Settlement Charges (\$3 million pre-tax) ⁽⁴⁾	0.01	-					
Financing Costs (\$5 million pre-tax) ⁽³⁾	-	0.02					
Employee Termination Cost-related Amounts (\$5 million pre-tax) ⁽⁵⁾	-	(0.02)					
Income Tax Benefit of Special Items (\$(106) million and \$(169) million)	(0.49)	(0.79)					
Adjusted Diluted Earnings per Share	\$ 2.35	\$ 2.05	\$ 0.30	\$ (0.10)	\$ 0.40	14.6%	19.5%

⁽¹⁾ Includes non-cash amortization expense of \$131 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of (\$0) million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$4 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

⁽²⁾ Represents non-cash amortization expense of \$148 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$291 million pre-tax to reflect CareFusion's inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date.

⁽³⁾ Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

⁽⁴⁾ Represents pension settlement charges associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost.

⁽⁵⁾ Represents an adjustment to the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014.



Q3 YTD 2016 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

(Unaudited)

	Nine Months Ended June 30,						
	2016	2015	Growth	Foreign Currency Translation	Foreign Currency Neutral Growth	Growth %	Foreign Currency Neutral Growth %
Reported Diluted Earnings per Share	\$ 4.41	\$ 2.52	\$ 1.89	\$ (0.51)	\$ 2.40	75.0%	95.2%
Purchase Accounting Adjustments (\$395 million and \$466 million pre-tax, respectively)	1.82 ⁽¹⁾	2.28 ⁽²⁾					
Restructuring Costs (\$198 million and \$136 million pre-tax, respectively) ⁽³⁾	0.91	0.67					
Integration Costs (\$115 million and \$55 million pre-tax, respectively) ⁽³⁾	0.53	0.27					
Transaction Costs (\$7 million and \$52 million pre-tax, respectively) ⁽³⁾	0.03	0.26					
Pension Settlement Charges (\$3 million pre-tax) ⁽⁴⁾	0.01	-					
Financing Costs (\$107 million pre-tax) ⁽³⁾	-	0.53					
Employee Termination Cost-related Amounts (\$5 million pre-tax) ⁽⁵⁾	-	(0.02)					
Litigation-related Charge (\$12 million pre-tax) ⁽⁶⁾	-	0.06					
Income Tax Benefit of Special Items (\$270 million and \$277 million)	(1.24)	(1.36)					
Dilutive Share Impact ⁽⁷⁾	-	0.02					
Adjusted Diluted Earnings per Share	\$ 6.48	\$ 5.22	\$ 1.26	\$ (0.51)	\$ 1.77	24.1%	33.9%

⁽¹⁾ Includes non-cash amortization expense of \$416 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$5 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$26 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

⁽²⁾ Includes non-cash amortization expense of \$184 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$291 million pre-tax to reflect CareFusion's inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes an acquisition-date accounting gain of \$9 million pre-tax related to a previously held equity investment.

⁽³⁾ Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

⁽⁴⁾ Represents pension settlement charges associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost.

⁽⁵⁾ Represents an adjustment to the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014.

⁽⁶⁾ Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

⁽⁷⁾ Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-date adjusted diluted average shares outstanding (in thousands) is 197,390.



FY 2016 Reconciliation – FX Impact Emerging and Developed Markets

(Unaudited; Amounts in millions)

	Emerging Markets*						Developed Markets					
	Q1	Q2	Q3	Q3 YTD	Q4	Full Year	Q1	Q2	Q3	Q3 YTD	Q4	Full Year
A	BDX Reported 2016						2,521 2,625 2,713 7,858					
B	Deferred Revenue						6 4 2 12					
A+B	BDX Adjusted 2016						2,527 2,628 2,715 7,870					
	<i>Adjusted Comparable Growth %</i>						<i>(2.4) 2.8 3.7 1.4</i>					
	<i>FX Neutral Growth %</i>						<i>1.7 5.3 3.7 3.5</i>					
	<i>FX Impact %</i>						<i>(4.1) (2.5) 0 (2.2)</i>					
C	Comparable As Reported 2015						2,611 2,581 2,629 7,821 2,570 10,391					
D	Respiratory Adjustment **						(23) (23) (25) (71) (7) (78)					
E	Deferred Revenue						- - 13 13 8 20					
C+D+E	Comparable Adjusted 2015						2,588 2,558 2,617 7,762 2,571 10,334					
	<i>Adjusted Comparable Growth %</i>						<i>5.3 0.3 (5.2) (0.1) (1.0) (0.3)</i>					
	<i>FX Neutral Growth %</i>						<i>7.9 4.9 1.2 4.6 5.0 4.7</i>					
	<i>FX Impact %</i>						<i>(2.6) (4.6) (6.4) (4.6) (6.0) (5.0)</i>					

* Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and certain countries within Asia Pacific, excluding Australia, New Zealand, Korea, Singapore, Hong Kong, Taiwan & Japan.

** To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.



FY 2016 Reconciliation – FX Impact Emerging Markets Safety and China

(Unaudited; Amounts in millions)

		Emerging Markets Safety*					
		Q1	Q2	Q3	Q3 YTD	Q4	Full Year
BDX Reported 2016		100	104	122	326		
<i>Adjusted Comparable Growth %</i>		(3.6)	2.9	11.7	3.8		
<i>FX Neutral Growth %</i>		10.9	15.6	19.6	15.4		
<i>FX Impact %</i>		(14.4)	(12.7)	(7.9)	(11.6)		
A+B	Comparable Historical 2015	104	101	109	314	110	424

* Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and certain countries within Asia Pacific, excluding Australia, New Zealand, Korea, Singapore, Hong Kong, Taiwan & Japan.

		China					
		Q1	Q2	Q3	Q3 YTD	Q4	Full Year
BD Reported 2016		163	163	170	496		
<i>Adjusted Comparable Growth %</i>		1.1	5.1	5.3	3.8		
<i>FX Neutral Growth %</i>		4.5	9.4	9.5	7.8		
<i>FX Impact %</i>		(3.3)	(4.3)	(4.2)	(3.9)		
Comparable Historical 2015		161	155	161	478	149	627
<i>Adjusted Comparable Growth %</i>		21.6	11.7	13.7	15.5	6.9	13.4
<i>FX Neutral Growth %</i>		22.2	14.1	13.9	16.6	8.4	14.6
<i>FX Impact %</i>		(0.6)	(2.5)	(0.2)	(1.1)	(1.5)	(1.2)



Q3 and Q3 YTD FY 2016 Safety Revenue

(Unaudited; Amounts in millions)

	Three Months Ended June 30,				
	A	B	C	D=(A-B)/B	E=(A-B-C)/B
	As Reported		FX	% Change	
	2016	2015	Impact	Reported	FXN
TOTAL SAFETY REVENUES					
United States	\$ 450	\$ 427	\$ -	5.3	5.3
International	334	302	(9)	10.8	13.9
TOTAL	\$ 784	\$ 729	\$ (9)	7.6	8.9
BY SEGMENT					
BD Medical	\$ 493	\$ 454	\$ (5)	8.6	9.6
BD Life Sciences	291	275	(5)	5.9	7.6
TOTAL	\$ 784	\$ 729	\$ (9)	7.6	8.9

	Nine Months Ended June 30,				
	A	B	C	D=(A-B)/B	E=(A-B-C)/B
	As Reported		FX	% Change	
	2016	2015	Impact	Reported	FXN
TOTAL SAFETY REVENUES					
United States	\$ 1,340	\$ 1,030	\$ -	30.1	30.1
International	914	823	(79)	11.1	20.7
TOTAL	\$ 2,254	\$ 1,852	\$ (79)	21.7	25.9
BY SEGMENT					
BD Medical	\$ 1,425	\$ 1,031	\$ (41)	38.2	42.2
BD Life Sciences	829	822	(37)	0.9	5.4
TOTAL	\$ 2,254	\$ 1,852	\$ (79)	21.7	25.9

	Nine Months Ended June 30,					
	A	B	C	D=B+C	E	F=(A-D-E)/D
	BD	BD	CFN	Comparable	Comparable	Comparable
	Reported	Reported	Reported	Historical	FX	FXN
	2016	2015	1st Half 2015*	2015	Impact	% Change
TOTAL SAFETY REVENUES						
United States	\$ 1,340	\$ 1,030	\$ 252	\$ 1,281	\$ -	4.6
International	914	823	79	902	(79)	10.1
TOTAL	\$ 2,254	\$ 1,852	\$ 331	\$ 2,184	\$ (79)	6.8
BY SEGMENT						
BD Medical	\$ 1,425	\$ 1,031	\$ 331	\$ 1,362	\$ (41)	7.7
BD Life Sciences	829	822	-	822	(37)	5.4
TOTAL	\$ 2,254	\$ 1,852	\$ 331	\$ 2,184	\$ (79)	6.8

* For the quarters ended December 31, 2014 and March 31, 2015



Q3 YTD FY 2016 Adjusted FXN Revenues

(Unaudited; Amounts in millions)

		2016			
		Q1	Q2	Q3	Q3 YTD
A	<u>BDX As Reported Revenues</u>	2,986	3,067	3,198	9,252
B	Deferred Revenue	6	4	2	12
A+B	<u>BDX As Adjusted Revenues</u>	2,992	3,071	3,200	9,263
C	FX Impact	(162)	(113)	(29)	(304)
A+B-C	<u>BDX As Adjusted FXN Revenues</u>	3,155	3,184	3,229	9,567



FY 2016+ Product Launches

Medical Segment Program / Product	Planned Launch Date
<ul style="list-style-type: none"> • BD Insulin Infusion Sets • Pyxis Mini 	<ul style="list-style-type: none"> ➤ FY 2016 ➤ FY 2016
Life Sciences Segment Program / Product	Planned Launch Date
<ul style="list-style-type: none"> • BD MAX™ – Extended Enteric Bacterial • BD MAX™ – Enteric Viral • BD MAX™ – GC/CT and GC/CT/Trich • BD MAX™ – Vaginitis / Vaginosis • BD Veritor™ – Next Generation • BD Totalys™ • BD Horizon™ (Sirigen) Dyes • BD FACSCelesta™ • BD FACSLyric™ • BD FACSseq™ • BD CLiC™ LP • BD Barricor™ • BD UltraTouch™ PBBCS 	<ul style="list-style-type: none"> ➤ FY 2016 EU / FY 2017 U.S. ➤ FY 2017 EU / FY 2017 U.S. ➤ FY 2016 U.S. ✔ FY 2016 EU launch; ➤ FY 2016 U.S. Launch ➤ FY 2016 ✔ FY 2016 U.S. Launch ✔ Q1 FY 2016 ✔ 1H FY 2016 ✔ Q3 FY 2016 EU launch ➤ FY 2017 (Delay) ➤ FY 2016 ✔ Launched x-U.S.; FY 2016 U.S. ✔ FY 2016

